164 related articles for article (PubMed ID: 31692424)
1. Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures.
Korani M; Korani S; Zendehdel E; Nikpoor AR; Jaafari MR; Orafai HM; Johnston TP; Sahebkar A
Curr Pharm Des; 2019; 25(46):4883-4892. PubMed ID: 31692424
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
Robak P; Robak T
Drugs R D; 2019 Jun; 19(2):73-92. PubMed ID: 30993606
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature.
Vora PA; Patel R; Dharamsi A
Recent Pat Anticancer Drug Discov; 2020; 15(2):113-131. PubMed ID: 32234004
[TBL] [Abstract][Full Text] [Related]
5. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
7. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
Liu J; Zhao R; Jiang X; Li Z; Zhang B
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
9. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Shen S; Du XJ; Liu J; Sun R; Zhu YH; Wang J
J Control Release; 2015 Jun; 208():14-24. PubMed ID: 25575864
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
J Microencapsul; 2021 May; 38(3):192-202. PubMed ID: 33530812
[TBL] [Abstract][Full Text] [Related]
11. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
12. Targeting the ubiquitin-proteasome pathway in cancer therapy.
Ishii Y; Waxman S; Germain D
Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
14. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
15. Proteasome as an emerging therapeutic target in cancer.
Zavrski I; Kleeberg L; Kaiser M; Fleissner C; Heider U; Sterz J; Jakob C; Sezer O
Curr Pharm Des; 2007; 13(5):471-85. PubMed ID: 17348844
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib in the treatment of mantle cell lymphoma.
Robak T
Future Oncol; 2015; 11(20):2807-18. PubMed ID: 26347482
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in the treatment of cancer.
Roccaro AM; Vacca A; Ribatti D
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):397-403. PubMed ID: 18221049
[TBL] [Abstract][Full Text] [Related]
18. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R; Foster JB; Teachey DT
Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y
Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367
[TBL] [Abstract][Full Text] [Related]
20. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
